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The prevalence of neurodegenerative disease has increased significantly in recent years,
and with a rapidly aging global population, this trend is expected to continue. These
diseases are characterised by a progressive neuronal loss in the brain or peripheral
nervous system, and generally involve protein aggregation, as well as metabolic
abnormalities and immune dysregulation. Although the vast majority of
neurodegeneration is idiopathic, there are many known genetic and environmental
triggers. In the past decade, research exploring low-grade systemic inflammation and
its impact on the development and progression of neurodegenerative disease has
increased. A particular research focus has been whether systemic inflammation arises
only as a secondary effect of disease or is also a cause of pathology. The inflammasomes,
and more specifically the NLRP3 inflammasome, a crucial component of the innate
immune system, is usually activated in response to infection or tissue damage.
Dysregulation of the NLRP3 inflammasome has been implicated in the progression of
several neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease, amyotrophic lateral sclerosis, and prion diseases. This review aims
to summarise current literature on the role of the NLRP3 inflammasome in the
pathogenesis of neurodegenerative diseases, and recent work investigating NLRP3
inflammasome inhibition as a potential future therapy.
Keywords: neurodegenerative disease, NLRP3 inflammasome, Alzheimer's disease, Parkinson’s disease,
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INTRODUCTION
Neurodegenerative disease is an increasingly common societal issue, especially in countries with an
aging population. These diseases are heterogeneous in their clinical presentations (Table 1), with a
diverse range of underlying mechanisms, resulting in a variety of underlying pathophysiologies
(Dugger and Dickson, 2017). However, despite their heterogeneous nature, systemic activation of the
immune system remains a common feature that is implicated in the progression of many of these
diseases (Figure 1) (Amor et al., 2010). This is further complicated by the observation that immune
activation can function as a double-edged sword, whereby in some contexts it acts as an aid to cellular
repair and regeneration, such as clearance of debris by microglia (Jin and Yamashita, 2016), whereas
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in others, it may be detrimental (Kempuraj et al., 2016).
Furthermore, the central nervous system (CNS) has, until
relatively recently, been considered an immune privileged site;
however, the discovery of a functional meningeal lymphatic
system, that allows movement of cerebrospinal fluid (CSF) to
the cervical lymph nodes, has challenged this view and further
emphasised the importance of the immune system in the
pathology of neurodegenerative disease (Louveau et al., 2015).
The NLRP3 inflammasome is a multimeric protein complex,
which assembles in response to homeostasis-altering molecular
patterns (HAMPs), pathogen-associated molecular patterns
(PAMPs) and danger-associated molecular patterns (DAMPs),
and functions as a centrally important component of the innate
immune system (Figure 2) (Martinon et al., 2002; Liston and
Masters, 2017; Kelley et al., 2019). It consists of three main
components: an apoptosis-associated speck-like protein
containing a CARD (caspase activation and recruitment
domain) (ASC), which functions as a central adaptor protein;
an inflammatory caspase, caspase-1, and a pattern recognition
receptor (PRR) protein, NLRP3 (nucleotide-binding domain
(NOD)-like receptor protein 3) (Kelley et al., 2019). There are
several different inflammasomes, all defined by the PRRs they
contain; however, this review will focus specifically on the NLRP3
inflammasome (Zheng et al., 2020). Upon activation, via
detection of PAMPs or DAMPs, these various components
undergo conformational change to subsequently assemble and
nucleate the oligomerisation of monomeric PRR proteins (Lu
et al., 2014) and form the NLRP3 inflammasome. This large
multimeric protein comple acts via caspase-1 dependent
proteolytic cleavage of several proteins, including pro-
interleukin (pro-IL)-18 and pro-IL-1β to their mature
inflammatory cytokines, IL-18 and IL-1β (Kelley et al., 2019).
IL-18 is important for interferon-γ (IFNγ) production as well as
negative regulation of the Th17 cell population and promotion of
key Treg cell generation, thereby playing an important role in the
regulation of intestinal inflammation and adaptive immunity
(Harrison et al., 2015). By contrast, IL-1β induces fever,
sensitises neutrophils to chemoattractants, stimulates
vasodilation, and increases the expression of adhesion
molecules, thereby facilitating the infiltration of immune cells
into damaged or infected tissues (Kelley et al., 2019).
Furthermore, gasdermin D (GSDMD) also undergoes
NLRP3 inflammasome-dependent cleavage, which facilitates
GSDMD’s insertion into cellular membranes to form pores,
thus initiating a specific kind of cell death called pyroptosis
(Fink and Cookson, 2006).
In recent years, our understanding of NLRP3 inflammasome
activation and regulation has rapidly progressed, leading the way
to new developments in potential therapeutics for several
autoinflammatory diseases (Caseley et al., 2020). This review
aims to summarise recent progress in our understanding of
several neurodegenerative diseases, whose development and/or
progression has been linked to inflammation involving activation
TABLE 1 | Neurodegenerative disease. Showing typical age of onset, symptoms and primary areas of central nervous system (CNS) involvement.




Symptoms Primary area of CNS
effected




Episodic memory deficits, apathy and depression are early symptoms.
Later symptoms include impaired communication, disorientation,
confusion, poor judgment, behavior changes and, ultimately, difficulty
speaking, swallowing and walking
Entorhinal cortex, hippocampus,
cerebral cortex




Bradykinesia, muscle rigidity, tremors, impaired posture and balance.
Non-motor disturbances such as motivation and memory
Substantia nigra
Huntington’s ∼35 ∼2.7 per 100,000 Progressive chorea, cognitive decline and psychiatric disorders. Basal ganglia and cerebral cortex
Amyotrophic lateral
sclerosis
∼65 ∼2.2 per 100,000 Muscle weakness and progressive paralysis, respiratory insufficiency Brain stem, spinal cord and
primary motor cortex
Prion diseases ∼60 ∼0.1–0.2 per
100,000
Loss of intellect andmemory, personality changes, slurred speech, loss
of balance/coordination, vision problems, abnormal jerking
movements, progressive cognitive impairment and mobility
Cerebral cortex
FIGURE 1 | Common dysregulated mechanisms underlying
neurodegenerative diseases. Demonstrating the similarities between the
dysregulatedmechanisms underlying each of the neurodegenerative diseases
covered in this review. These overlapping disease mechanisms suggest
that similar therapeutics could be utilised to treat several of these conditions.
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FIGURE 2 | NLRP3 inflammasome activation in neurodegenerative disorders. The NLRP3 inflammasome assembles in response to two signals; toll-like receptor 4
(TLR4) stimulation by LPS induces the NF-κβ-mediated transcription of pro-IL-1β and pro-IL-18, and stimuli such as P2X7 receptor-facilitated potassium (K+) efflux
trigger NLRP3 inflammasome activation. The activated NLRP3 inflammasome recruits an adaptor protein, apoptosis-associated speck-like protein containing a CARD
(ASC), and oligomerises to activate caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their active forms. Disease-related proteins can also activate the NLRP3
inflammasome. Phagocytosis of fibrillar β-amyloid (Aβ) (Alzheimer’s disease) causes NLRP3 inflammasome activation via lysosomal damage and cathepsin B release. Aβ
also binds to ASC specks released during inflammasome activation, increasing the formation of Aβ oligomers. Tau monomers and oligomers (Alzheimer’s disease)
activate the NLRP3 inflammasome, which, in turn, affects tau hyperphosphorylation and aggregation. Phagocytosis of aggregated α-synuclein (Parkinson’s disease)
results in NLRP3 inflammasome activation, and uptake of aggregated α-synuclein, mediated by Fyn kinase and the class B scavenger receptor CD36, facilitates LPS-
independent inflammasome priming. α-synuclein is also associated with mitochondrial dysfunction, including mitochondrial DNA (mtDNA) disturbances. Mutant SOD1
(ALS) acts as a DAMP to activate the NLRP3 inflammasome. Transactive response DNA-binding protein-43 (TDP-43) (ALS) causes CD14-induced NF-κβ activation, and
triggers mtDNA release. In prion diseases, aggregated and fibrillar forms of the neurotoxic PrP-derived peptide (PrP106–126) are involved in NLRP3 inflammasome
priming, via triggering NF-κβ signaling, and activation. This NLRP3 inflammasome activation can be prevented by the NLRP3 specific inhibitor, MCC950, increasing the
extracellular K+ concentration to prevent K+ efflux, prevention of P2X7 receptor activation by CD39-mediated ATP hydrolysis, inhibition of mitochondrial reactive oxygen
species (mROS) by N-acetyl-l-cysteine and the anti-inflammatory hormone 17β-estradiol. The broad caspase inhibitor, zVAD-fmk, and the recombinant IL-1 receptor
antagonist, anakinra, both reduce the downstream effects of NLRP3 activation in disease.







MCC950 Walker B motif interaction and inhibition of ATP
hydrolysis
Fiala et al. (2002), Heneka et al. (2013), Liu and Wang (2017), Flores et al. (2018), Tzeng
et al. (2018), Antonyová et al. (2020)
Anti-ASC antibody Directly binds to ASC specks Daniels et al. (2016)
Anakinra Directly binds to IL-1 receptor, blocking IL-1β
function
Kadhim et al. (2016), Meissner et al. (2010)
17β-estradiol Unknown Bellezza et al. (2018)
Dopamine Binds to dopamine D1 receptor, inducing
ubiquitination of NLRP3
Rushworth et al. (2013)
Kaempferol NF-κB inhibition and ASC oligomerisation
inhibition
Elliott et al. (2018)
VX-765 Inhibits caspase-1 Venegas et al. (2017)
zVAD-fmk Inhibits caspase-1 Zhao et al. (2017)
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of the NLRP3 inflammasome. The review also considers the use of
novel therapeutics to target NLRP3 inflammasome activation,
with the possibility of modifying the clinical course of these
disorders (Table 2).
ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is the most common progressive age-
associated neurodegenerative disorder, characterised by
abnormal accumulation of protein aggregates in the form of
β-amyloid (Aβ)-containing plaques, and neurofibrillary tangles
composed of hyperphosphorylated tau (Blennow et al., 2006; De
Strooper and Karran, 2016). These protein aggregates are at first
found in the neocortex, but, over time, progress to the entorhinal
cortex and hippocampus (Thal et al., 2002) (Table 1). The
accumulation of aggregated protein, as in many other
neurodegenerative diseases, coincides with the activation of
microglia and astrocytes, which promote the release of
inflammatory molecules to aid cellular repair, as well as
phagocytosis of unwanted debris. However, sustained
activation of microglia and higher expression of inflammatory
molecules, particularly IL-1β, has been found in microglial cells
surrounding Aβ plaques, in AD patients as well as animal models
of disease (Figure 2) (Griffin et al., 1989; Simard et al., 2006).
Moreover, increased levels of IL-1β and IL-18 have also been
detected in the CSF of patients with AD (Blum-Degen et al.,
1995). There is evidence to suggest that both aggregated protein
accumulation and immune cell over-activation can compromise
the structure and function of neurons, resulting in episodic
memory deficits and cognitive impairment, characteristic of
AD (Blennow et al., 2006; Ising and Heneka, 2018; Feng et al.,
2020).
The NLRP3 inflammasome has been implicated as a key
commonent of the innate immune response in AD. The
evidence discussed below provides a clear basis for NLRP3
inflammasome inhibition/modulation to be considered as a
therapeutic strategy to delay progression of this disease.
Cultured monocytes, isolated from patients with AD, were
reported to have increased gene expression of NLRP3 as well
as ASC, caspase-1, and the cytokines, IL-1β and IL-18 (Saresella
et al., 2016), which suggests that the peripheral NLRP3-
mediated immune response is increased in disease. In line
with this, there is evidence to suggest that peripheral
monocytes can infiltrate the CNS in AD and accumulate near
areas of pathology (Figure 1) (Fiala et al., 2002). Using in vitro
models, activation of the NLRP3 inflammasome was found to be
initiated after fibrillar Aβ was phagocytosed by microglia,
leading to lysosomal damage with cathepsin B release,
caspase-1 activation and release of IL-1β as well as TNF and
nitric oxide (Halle et al., 2008). Consistent with these
observations, Henske et al., 2013 reported an increased
amount of active caspase-1 in brain lysates from AD patients
with mild cognitive impairment (MCI), relative to healthy
controls, suggestive of chronic inflammasome activation. In
the same study, using a transgenic mouse model of AD, aged
amyloid precursor protein (APP)/presenilin (PS1)M146V mice
were also found to have increased active caspase-1 levels. The
genetic ablation of NLRP3 or caspase-1 protected the APP/PS1
mice from spatial memory deficits, reducing brain levels of
caspase-1 and IL-1β, as well as enhancing microglial phagocytic
ability, thereby increasing Aβ clearance (Heneka et al., 2013).
Interestingly, NLRP3 inflammasome deficiency also skewed
microglial cells toward an M2 (anti-inflammatory)
phenotype, which correlated with decreased deposition of Aβ,
suggesting that microglia with an M2 phenotype may play a
protective role in AD (Heneka et al., 2013). Furthermore, long-
term neuronal changes in a mouse AD model, after acute
peripheral immune stimulation, were shown to be both
NLRP3 inflammasome and age-dependent (Beyer et al.,
2020). In another study, ASC specks, which are pivotal
components of the NLRP3 inflammasome, are released by
microglia during pyroptosis, and rapidly bind to Aβ,
increasing Aβ-oligomer formation and the spread of Aβ
pathology in APP/PS1 mice. ASC-deficient APP/PS1 mice, as
well as those administered with anti-ASC antibody, were able to
block the increase in Aβ pathology (Figure 2) (Venegas et al.,
2017). Collectively, these findings indicate that amyloid can
directly activate microglial NLRP3 inflammasome, which
triggers the chronic release of pro-inflammatory cytokines
and ASC specks, and promote the development of AD
pathology.
Direct inhibition of the NLRP3 inflammasome with the small
molecule inhibitor, MCC950, also known as CRID3, improved
cognitive function and reduced Aβ accumulation, as well as
promoting Aβ clearance in APP/PS1 mice (Figure 2) (Dempsey
et al., 2017). Triple-transgenic (3 × Tg)ADmice provide a unique
model of AD, as they contain the human APP Swedish mutant
transgene, tau (P301L), and PS1(M146V) knock-in mutation.
Indirect inhibition of NLRP3 inflammasome activation in 3 ×
TgAD mice using the fenamate non-steroidal anti-inflammatory
drug, mefanamic acid, completely abrogated the AD-related
neuroinflammation, with levels of IL-1β expression and
microglial activation reduced to wild-type levels. Fenamates
suppress chloride efflux via the volume regulated anion
channel (VRAC), which, in turn, blocks NLRP3 activation
and IL-1β release (Daniels et al., 2016). In another study,
inhibition of caspase-1 activity with VX-765 dose-
dependently reversed episodic and spatial memory
impairment and reversed brain inflammation and Aβ
deposition in the J20 mouse model of AD (Flores et al.,
2018). Interestingly, although NLRP3 deletion and
caspase-1 inhibition appears to protect against amyloid-
induced AD-like disease, IL-18 deletion did not protect
APP/PS1 mice. Instead, IL-18-deficient AD mice were
more susceptible to aberrant neuronal transmission in AD
(Tzeng et al., 2018).
The impact of tau on activation of the NLRP3 inflammasome
hasn’t been explored to the same extent as Aβ, but a recent article
by Stancu et al., in 2019 demonstrated that tau seeds are able to
activate the NLRP3 inflammasome in primary microglia, and that
ASC deficiency in tau transgenic mice inhibited the seeding of tau
pathology. Intracerebral administration of MCC950 inhibited
exogenously seeded tau pathology (Heneka et al., 2013; Stancu
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et al., 2019). In another study, tau monomers and oligomers were
found to activate the NLRP3 inflammasome, an effect which
could be inhibited by MCC950 (Ising et al., 2019). The loss of
NLRP3 inflammasome function reduced tau
hyperphosphorylation and aggregation, a phenomenon which
could be attributed to IL-18, a known inducer of kinases, Cdk5
and glycogen synthase kinase-3β (GSK-3β), which are involved in
the hyperphosphorylation of tau (Ojala et al., 2008). Tau
monomers/oligomers could therefore activate the NLRP3
inflammasome, and subsequent injection with fibrillar Aβ-
containing brain homogenates could induce tau seeding and
pathology. Together, these data suggest that neurofibrillary
tangles develop downstream of Aβ-induced microglial
activation (Ising and Heneka, 2018).
Previous studies have described the pathogenic role of IL-1β
in AD, with IL-1β cerebral injection raising amyloid precursor
protein (APP) levels in wild-type mice (Sheng et al., 1996). In
mice with a deficiency of IL-1Ra, subsequent intra-
cerebroventricular injection with oligomeric Aβ1-42 resulted
in mice which were more vulnerable to Aβ oligomers (Craft
et al., 2005). However valid, these studies were based on acute
injection of IL-1β or Aβ oligomers and only provide indirect
evidence of the involvement of IL-1 signaling in AD. It is likely
that in AD, the increase in IL-1β is a chronic process which
develops over months/years (Shaftel et al., 2007). Shaftel et al.,
in 2007, found that sustained over-expression of IL-1β in APP/
PS1 mice reduced plaque pathology, possibly due to increased
phagocytic activity of microglia and macrophages (Shaftel
et al., 2007). In a later study, although sustained expression
of IL-1β reduced amyloid load in 3xTgAD mice, kinases and
phosphatases, involved in tau phosphorylation, were found to
be increased (Ghosh et al., 2013). Therefore, while IL-1β may
be beneficial in the first instance to clear amyloid deposition,
the underlying increase in tau phosphorylation may drive both
tau and amyloid pathology, via activation of the NLRP3
inflammasome. These data are consistent with other
investigations whereby modulation of innate immunity in
vivo caused a reduction of Aβ, with a corresponding
increase in microglial activation. For example, intracranial
administration of lipopolysaccharide (LPS) in a mouse
model of AD leads to a reduction in amyloid pathology
through microglial clearance of Aβ (DiCarlo et al., 2001;
Herber et al., 2004). A recent study by Wendeln et al., in
2018, explored whether peripheral stimulation of LPS could
trigger innate immune memory in brain microglia. Using the
APP23 murine AD model, which develops insoluble amyloid
plaques at 6 months of age, subcutaneous injection of a low
dose of LPS at 3 months of age increased the number of
amyloid plaques at 6 months, whereas a 4 x dose of LPS
decreased the number of plaques, confirming that peripheral
immune stimuli can cause long-term alterations in brain
innate immune response, and can differentially affect the
development of Alzheimer’s pathology (Wendeln et al.,
2018). Trained immunity in the brain is a very interesting
phenomenon and, given that both infections and diseases, such
as diabetes or arthritis, are associated with chronic
inflammatory processes and are considered as risk factors
for Alzheimer’s disease, epigenetically-modified microglia
could provide one possible explanation for this effect.
PARKINSON’S DISEASE
Parkinson’s disease (PD) is the second most common
neurodegenerative disease, with about 6 million people
affected worldwide (GBD, 2019). The characteristic
pathophysiology of PD involves loss of dopaminergic neurons
in the substantia nigra (SN) pars compacta resulting in a lack of
dopamine in the nigrostriatal system. This results in motor
symptoms including bradykinesia, muscle rigidity, and
tremors, as well as other non-motor disturbances such as loss
of motivation and low mood, which tend to respond well to
dopamine-replacing therapies (Massano and Bhatia, 2012)
(Table 1). However, CNS pathology in PD also extends
outside of the dopaminergic nigrostriatal system and involves
widespread non-dopaminergic pathways (Pfeiffer, 2016). This
leads to a number of other clinical features, such as dementia and
balance problems, which are unresponsive to dopamine replacing
therapies (Chaudhuri and Schapira, 2009). Neuronal dysfunction
in PD, in both subcortical and cortical regions, is accompanied by
intracellular aggregation of the α-synuclein protein to form Lewy
bodies. The precise role of these protein aggregates in cell
dysfunction, and why they form is still not fully known, but a
complex interplay of both environmental and genetic factors are
implicated, which impact on several essential cellular processes,
including mitochondrial physiology, lysosomal function and
autophagy (Figure 1) (Kitada et al., 1998; Valente et al., 2004;
Angeles et al., 2011; Wang et al., 2012; Kalia and Lang, 2015;
Chang et al., 2017; Alessi and Sammler, 2018).
Immune dysregulation has also been strongly implicated in
PD pathogenesis (Gao and Hong, 2008; Williams-Gray et al.,
2018), both systemically and within the central nervous system
(Tan et al., 2020). Genome-wide association studies (GWAS)
have reported a number of genetic variants, which are associated
with an increased risk of developing PD (Zabetian et al., 2007;
Pankratz et al., 2009; Satake et al., 2009; Simon-Sanchez et al.,
2009; Edwards et al., 2010; Hamza et al., 2010; Saiki et al., 2010;
Nalls et al., 2014; Pierce and Coetzee, 2017).
In PD, activated microglia have been found in the SN, and also
in more widespread subcortical and cortical regions (McGeer
et al., 1988; Imamura et al., 2003; Kouli et al., 2020), and are
implicated in neuronal toxicity, via secretions of inflammatory
cytokines as well as inducing astrocytes to release neurotoxic
elements (Liddelow et al., 2017). Furthermore, in patients with
PD, a pro-inflammatory profile of immune markers in the serum
at diagnosis is linked to a faster subsequent decline in motor
function and lower cognitive scores (Williams-Gray et al., 2016).
α-synuclein may play a critical role in driving peripheral immune
activation in PD (Sulzer et al., 2017; Scott et al., 2018; Schonhoff
et al., 2020; Wijeyekoon et al., 2020), which may be associated
with faster disease progression, presumably due to peripheral
immune cells and cytokines crossing the blood brain barrier to
promote microglial activation and neurotoxicity (Figure 1)
(Kouli et al., 2020).
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Similar to AD research, in recent years, there is mounting
evidence to specifically implicate the NLRP3 inflammasome in
PD disease progression. In human post-mortem brain from PD
cases, NLRP3 expression is elevated in mesencephalic neurons;
furthermore, NLRP3 genetic polymorphisms are associated with
downregulation of NLRP3 activity and reduced risk of PD (von
Herrmann et al., 2018). In vitro work suggests possible
mechanistic links between NLRP3 activation and α-synuclein
aggregation; specifically, activation of the NLRP3 inflammasome
in the neuronal cell line, BE(2)-M17, that overexpresses
α-synuclein, leads to aggregation of α-synuclein, which is
preventable by inhibition of caspase-1 (Figure 2) (Wang et al.,
2016). It was also found that, caspase-1 cleaves α-synuclein at
Asp121 in vitro, thereby predisposing α-synuclein to aggregate.
Moreover, caspase-1 has been reported to co-localise with
α-synuclein in post-mortem PD brains (Wang et al., 2016).
Interestingly, caspase-1 and α-synuclein levels are also highly
correlated in human serum, and both are lower in PD than
controls, suggesting that they may be co-sequestered out of serum
into intracellular aggregates (Wijeyekoon et al., 2020). It has also
been reported that newly diagnosed PD patients have increased
systemic IL-1β levels in the serum (Williams-Gray et al., 2016),
and systemic NLRP3 inflammasome expression and activation
are correlated with motor severity and progression in PD (Fan
et al., 2020). Furthermore, human monocytes have also been
shown to phagocytose aggregated α-synuclein, which leads to a
more pronounced NLRP3 inflammasome response (Codolo et al.,
2013). Fyn kinase, in conjunction with CD36, regulates microglial
uptake of aggregated α-synuclein thereby linking Fyn kinase and
CD36 activity to NLRP3-driven inflammation (Panicker et al.,
2019). Interestingly, Fyn kinase is also involved in the
phosphorylation of Tau at Tyr18 and is present in
neurofibrillary tangles in AD (Lee et al., 2004). Multiple
reports show Aβ-induced synaptic dysfunction involving the
tau-Fyn axis (Larson et al., 2012; Um et al., 2012; Um and
Strittmatter, 2013; Frandemiche et al., 2014; Nygaard, 2018);
specifically binding of Aβ oligomers to the cellular prion
protein (PrPC) on the surface of neurons directly activates Fyn
kinase, which in turn phosphorylates tau (Rushworth et al., 2013).
Fyn has also been implicated as a key regulator of tau pathology
independently of Aβ-induced toxicity (Briner et al., 2020). A
recent report found that OLT1177, a β-sulfonyl nitrile molecule,
is a selective inhibitor of the NLRP3 inflammasome, and in fact
reduces Fyn kinase levels by 35% in human monocyted derived
macrophages following stimulation with LPS and nigerecin
(Marchetti et al., 2018), and thus could be beneficial in both
AD and PD.
Mitochondrial dysfunction, such as reduced activity of
mitochondrial electron transport chain complex I, mutations
in mitochondrial quality control genes, and mtDNA
disturbances has been implicated in the pathogenesis of PD
(Bose and Beal, 2016; Matheoud et al., 2016; Antonyová et al.,
2020). Mitochondria are also key regulators of the NLRP3
inflammasome, with mitochondrial dysfunction resulting in
NLRP3 assembly and activation (Zhou et al., 2011; Elliott
et al., 2018). Impairment of mitochondrial function in
microglia has been found to amplify NLRP3 inflammasome
activity (Sarkar et al., 2017), with the NLRP3 inflammasome
being highly expressed in activated microglia, in post mortem PD
brains. Neurotoxins, aggregation of α-synuclein, mitochondrial
reactive oxygen species (mROS), and dysregulated mitophagy are
all key regulators of NLRP3 inflammasome activation, leading to
IL-1β and IL-18 release as well as pyroptotic cell death of neurons
in the SN (Wang et al., 2019; Haque et al., 2020). Furthermore, a
recent study demonstrated that the stimulation of mitophagy, in a
murine 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)
induced PD model, in an attempt to aid in clearance of damaged
mitochondria suppressed NLRP3 inflammasome activation in
microglia, reducing inflammation, dopaminergic neuronal loss
and improving behavioral parameters (Ahmed et al., 2020).
It is worth noting that dopamine has been reported to inhibit
NLRP3 inflammasome activation via the dopamine D1 receptor
(DRD1), as DRD1 signaling induces the binding of ubiquitin to
NLRP3, promoting its degradation (Yan et al., 2015). Hence loss
of dopamine in PD may facilitate NLRP3 activation, but,
conversely, dopamine-replacing medication may act to
suppress this. Other regulators of NLRP3 inflammasome
activation, with implications for PD etiology, include the long
noncoding RNA, lncRNA-Cox2, which regulates both autophagy
and microglial NLRP3 inflammasome activation via binding to
NF-κB, inducing its translocation to the nucleus and upregulation
of NLRP3 related genes (Xue et al., 2019). The knockdown of
lncRNA-Cox2 in microglia has been reported to reduce NLRP3
inflammasome activation and IL-1β secretion (Xue et al., 2019).
Also, the microbiota-gut-brain axis has been implicated in the
development of PD via enteric bacterial regulation of the NLRP3
inflammasome (Pellegrini et al., 2020), with heightened IL-1β
mRNA expression in the colon (Devos et al., 2013). Gut
inflammation may be an important driver of the systemic
immune response in PD.
This accumulating evidence suggests that specific modulation
of the NLRP3 inflammasome may be a promising therapeutic
target in PD (Haque et al., 2020). Indeed, NLRP3 inhibitors, such
as MCC950, simultaneously reduce microglial activation, motor
deficits, SN dopaminergic degeneration and accumulation of
α-synuclein aggregates, upon oral administration in mice that
have undergone injection of fibrillar α-synuclein in the striatum
(Gordon et al., 2018). Furthermore, NLRP3 inflammasome-active
microglia lead to neuronal cell death in a murine MPTP-induced
PD model (Lee et al., 2019), with KO of NLRP3 being found to
protect against dopaminergic neuronal loss in a similar toxin
based model (Ou et al., 2020), further emphasising the NLRP3
inflammasome's role in neurodegeneration. Another example of
NLRP3 modulation is via the use of kaempferol (Ka), a dietary
flavonoid and phyto-oestrogen, which reduces NLRP3
inflammasome activation and protects against
neurodegeneration, via upregulation of autophagy, in a murine
A53Ttg/tg α-synuclein overexpressing model (Han et al., 2019). Ka
has also been reported to reduce inflammation in a
neuroinflammation model, using a murine microglial cell line
(Park et al., 2011). However, this proposed mechanism is
complicated by the fact that other work has implicated
α-synuclein-mediated promotion of autophagy in activating
the NLRP3 inflammasome in astrocytes extracted from mouse
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brain tissue; also use of an autophagy inhibitor, 3-methyladenine,
led to decreased expression of NLRP3, caspase-1 and IL-1β
(Wang et al., 2020)., Another in vitro model, using murine
hippocampal HT22 cells, has demonstrated anti-inflammatory
properties of the cyclosporine A derivative, N-methyl-4-
isoleucine-cyclosporine (NIM811). NLRP3 inflammasome
activation and cell death, via mitochondrial damage, was
induced using rotenone and these effects were suppressed
upon addition of NIM811 (Zhang et al., 2020). Hence, NLRP3
inhibitors warrant further pre-clinical investigation in PD.
HUNTINGTON’S DISEASE
Huntington’s disease (HD) is an inherited autosomal-dominant
disorder, characterised by progressive chorea, cognitive decline
and psychiatric symptoms (Table 1). This neurodegenerative
condition is caused by a CAG-trinucleotide repeat expansion
in the huntingtin gene (HTT), that leads to production of
defective huntingtin protein, which misfolds and accumulates
within neurons, thus forming aggerates that affect normal cellular
function (Soto, 2003; Williams and Paulson, 2008). Although our
understanding of HD has grown in the last decade, existing
treatments for HD are limited to treating only the symptoms
of the disease, thus emphasising the urgent need to develop novel
therapeutic approaches to treat this disease.
Neuroinflammation is a known phenomenon in HD and is
likely to be involved in the pathophysiology of this condition
(Soulet and Cicchetti, 2011; Crotti and Glass, 2015; Rocha et al.,
2016; Palpagama et al., 2019). This neuroinflammation is believed
to be driven by microglia and other cells within the brain, and
unlike AD and PD, the presence of peripheral immune cells in the
brain is not a typical finding in HD (Figure 1) (Sapp et al., 2001;
Palpagama et al., 2019). Several oxidative stress and inflammatory
markers are raised in the serum of patients with HD, including
CRP, GM-CSF, TNF, IL-1β, IL-6 and IL-8, strongly suggesting an
inflammatory phenotype in this neurological disorder (Björkqvist
et al., 2008; Sánchez-López et al., 2012; Chang et al., 2015; Politis
et al., 2015; Rodrigues et al., 2016). Further investigations have
revealed localised brain inflammation in HD with high levels of
TNF, IL-1β, IL-6 and IL-8 in several regions of the brain,
including the striatum, cortex and cerebellum (Björkqvist
et al., 2008; Silvestroni et al., 2009; Rodrigues et al., 2016).
Interestingly, plasma levels of IL-18 were significantly reduced
in patients with HD and also in the R6/2 HD mice model (Chang
et al., 2015). Although IL-1β and IL-18 cytokines are typically
released post activation of the NLRP3 inflammasome, the
divergent levels of these two cytokines in HD suggest different
roles. In fact, some studies indicate that different regulatory
mechanisms control IL-1β and IL-18 secretion (Schmidt and
Lenz, 2012; Zhu and Kannegant, 2017; Christgen et al., 2020),
which is an important consideration in understanding their
effects in several neurological disorders, including HD (Motta
et al., 2007; Chang et al., 2015; Tzeng et al., 2018; De Biase et al.,
2020).
The fact that IL-1β is raised in HD strongly suggests
involvement of the NLRP3 inflammasome; one study has
shown that NLRP3 expression is significantly increased in
peripheral blood mononuclear cells (PBMCs) from patients
with HD when compared to healthy subjects (Glinsky, 2008).
Siew et al. showed that galectin-3 is a critical mediator of the
neuroinflammation observed in HD, which is driven by
microglial cells via NF-κB and NLRP3 inflammasome-
dependent pathways (Siew et al., 2019). Moreover, this study
revealed that plasma levels of galectin-3 correlate with disease
activity in patients with HD and also in HD mice models (Siew
et al., 2019). Remarkably, galectin-3 KO in mice significantly
increased the survival of mice with HD as well as reducing
inflammation, huntingtin protein aggregation and motor
dysfunction.
Activation of the unfolded protein response (UPR) in HD
(Duennwald and Lindquist, 2008; Leitman et al., 2013; Kalathur
et al., 2015) may be associated with the increased levels of IL-1β
associated with induction of the NLRP3 inflammasome, as the
NLRP3 inflammasome can be activated in both UPR-dependent
and independent fashions (Menu et al., 2012; Oslowski et al.,
2012). Activation of the NLRP3 inflammasome can be achieved
by dimerisation and phosphorylation of inositol-requiring
enzyme 1α (IRE1α) which, in turn, enables thioredoxin-
interacting protein (TXNIP) to activate the NLRP3
inflammasome, resulting in caspase-1 cleavage and IL-1β
secretion (Lerner et al., 2012; Abderrazak et al., 2015; Chen
et al., 2018; Llanos-González et al., 2020).
There are still several knowledge gaps which need to be
elucidated in the pathogenesis of HD, such as the origin of the
neuroinflammation and whether inhibition of inflammation
would effectively reduce the progression of this condition. It
would be interesting to explore whether NLRP3 inhibition, or the
use of other immunosuppressants, could reduce the
pathophysiology of HD.
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset
neurodegenerative disease characterised by a progressive
degeneration of motor neurons within the brain stem, spinal
cord and primary motor cortex (Table 1). Most ALS cases are
sporadic (sALS), with familial ALS (fALS) contributing
approximately 10% of cases (Ghasemi and Brown, 2018).
Superoxide dismutase 1 (SOD1) mutations account for around
20% of fALS cases (Andersen, 2006) and represent the majority of
animal models (Philips and Rothstein, 2015), the most common
being a transgenic mouse expressing the human SOD1(G93A)
mutant (Morrice et al., 2018). Neuroinflammation is increasingly
associated with ALS pathogenesis (Liu and Wang, 2017), and,
although there is evidence to implicate the NLRP3
inflammasome, its fundamental role remains unclear.
SOD1(G93A) mice display upregulated NLRP3, active
caspase-1, IL-1β and IL-18 which correlate with dendritic
swelling and neuronal loss in the brain (Figure 2) (Debye
et al., 2018; Gugliandolo et al., 2018). Progression from pre-
symptomatic to early-symptomatic ALS is associated with
upregulated Nlrp3 and IL-1β gene expression, increased
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NLRP3 and ASC protein expression and mature IL-1β release in
the SOD1(G93A) mouse spinal cord (Johann et al., 2015; Cunha
et al., 2018), and NLRP3 protein expression, caspase-1 cleavage
and mature IL-1β secretion in microglia is significantly increased
in response to LPS (Bellezza et al., 2018). An increase in
inflammatory markers is also seen in ALS patients; both sera
and CSF samples exhibit significantly elevated IL-18 levels
(Italiani et al., 2014), and caspase-1 levels in ALS patients’ sera
are higher than in healthy controls (Iłzecka et al., 2001). However,
evidence directly linking this inflammation to NLRP3 activity is
limited. ALS patients’ monocytes show increased inflammatory
gene expression, including NLRP3 and IL-18 (Zhao et al., 2017),
and elevated in-situ expression of NLRP3, activated caspase-1 and
IL-18 have been identified in post-mortem brain samples from
sALS patients; however, it is unclear whether this is significant as
they were compared to a single non-ALS counterpart (Kadhim
et al., 2016). Increased levels of NLRP3, ASC and mature IL-1β
have also been observed in human spinal cord tissue samples,
although this did not reach significance levels in the case of
NLRP3 (Johann et al., 2015).
One specific mechanism proposed to connect the NLRP3
inflammasome with ALS pathology is that misfolded proteins
may act as inflammasome-stimulating DAMPs. Extracellular
human SOD1(G93A) or SOD1(G85R), but not wild type SOD1,
activates caspase-1 and causes mature IL-1β release when
phagocytosed by mouse microglia and macrophages (Meissner
et al., 2010; Zhao et al., 2010). TLR4 and CD14 pathways are
required for this inflammatory cytokine release (Zhao et al.,
2010), as is ASC (Meissner et al., 2010; Zhao et al., 2010), thus
implicating an ASC-containing inflammasome. However, it is
unclear whether NLRP3 is specifically involved. Meissner et al.
found that caspase-1–mediated IL-1β release, in response to
SOD1(G93A), occurs independently of LPS priming and NLRP3
(Meissner et al., 2010). By contrast, a recent study showed that
NLRP3, expressed inmicroglia from SOD1(G93A)mice, is activated
by aggregated and soluble SOD1(G93A) protein, leading to ASC
speck formation, caspase-1 cleavage and mature IL-1β secretion.
This SOD1(G93A)-mediated inflammation also involved ROS,
ATP-mediated P2X7 receptor activation, with attenuation by the
NLRP3-specific inhibitor MCC950, strongly suggesting that the
NLRP3 inflammasome plays an essential role in the process
(Deora et al., 2020).
Transactive response DNA-binding protein-43 (TDP-43) is
also implicated in ALS pathology, as it forms a major component
of intraneuronal aggregates in most ALS patients (Prasad et al.,
2019), as well as triggering mtDNA release, acting as a trigger for
the NLRP3 inflammasome (Yu et al., 2020). Extracellular TDP-43
causes activation of murine microglia and initiates a
proinflammatory cascade featuring upregulation of NLRP3,
active caspase-1 and mature IL-1β release. Co-culture of TDP-
43-activated microglia with motor neurons causes motor neuron
death, providing evidence that this protein may cause
neurotoxicity via an NLRP3 inflammasome-related mechanism
(Zhao et al., 2015). Conversely, the anti-inflammatory signaling
hormone, 17β-estradiol, which has been linked to the lower
incidence of ALS in women (de Jong et al., 2013), may have
an inverse effect and improve motor performance by reducing
NLRP3 inflammasome expression and function, with associated
motor neuronal cell survival (Heitzer et al., 2017). TDP-43 has
also been implicated in the onset and development of AD
(Vanden Broeck et al., 2014; Budini et al., 2017), and various
pathogenic mechanisms underlying AD, including the deposition
of Aβ (LaClair et al., 2016; Davis et al., 2017), tau
hyperphosphorylation (Davis et al., 2017; Gao et al., 2018),
mitochondrial dysfunction (Izumikawa et al., 2017), and
neuroinflammation (Herman et al., 2012); thus TDP-43 could
also potentially trigger the NLRP3 inflammasome in AD, which
warrants further investigation.
Evidence for the potential of the NLRP3 inflammasome as a
therapeutic target in ALS varies between species. Knockout or
inhibition of caspase-1, IL-1β or TLR4 delays symptomatic
progression and mortality in SOD1(G93A) mice (Friedlander
et al., 1997; Meissner et al., 2010; Lee et al., 2015), but does not
affect disease onset, whereas the pan-caspase inhibitor, zVAD-
fmk, delays both onset and mortality (Li et al., 2000). However,
trials in humans with the recombinant IL-1 receptor antagonist,
anakinra, have been less successful. In a case study of a patient
suffering from severe idiopathic cold urticaria and ALS-linked
neurological symptoms, anakinra caused remission of the CAPS-
like symptoms but did not influence neurological symptoms
(Bodar et al., 2009). Additionally, a pilot study assessing the
safety of anakinra in 17 ALS patients found no overall difference
in disease progression (Maier et al., 2015). This may be due to the
dose used; 1–2 mg/kg was used in humans compared to
75–150 mg/kg in the mouse studies described above. As such,
further studies assessing alternative IL-1 inhibitors with different
therapeutic properties, as well as specific NLRP3 inhibitors,
would help to assess the value of targeting this inflammasome
in ALS (van der Meer and Simon, 2010).
PRION DISEASES
Prion diseases are a group of fatal neurodegenerative disorders of a
genetic, sporadic or infectious nature, all of which are caused by
misfolding of the PrPC into a pathological isoform (PrPSc). These
diseases are characterised by spongiform degeneration, astrocytic
gliosis, neuronal loss and the decay of cognitive function (Prusiner,
1998). Sporadic Creudzfeldt-Jakob disease (CJD)manifests between
55 and 75 years with rapidly progressing dementia, and several
behavioral symptoms including delusions, hallucinations,
depression, disorientation and memory loss (Table 1) (Chandra
et al., 2016). Neuronal loss in CJD is mainly caused by an apoptotic
event following the accumulation of misfolded prions (Giese et al.,
1995; Gray et al., 1999a; Gray et al., 1999b). The number of
apoptotic neurons has been shown to correlate with the number
of activated microglia and, in turn, with the severity of
neuropathological lesions (Van Everbroeck et al., 2002). In line
with this, increased levels of inflammatory cytokines including IL-8,
CCL2, TGFβ, TNF and IL-1β have been found in the CSF of
sporadic CJD cases (Sharief et al., 1999; Van Everbroeck et al., 2002;
Stoeck et al., 2006; Stoeck et al., 2014), with increased IL-1β levels
correlating with the number of activated microglia at early stages of
the disease (Van Everbroeck et al., 2002).
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In 2012, two in vitro studies reported that aggregated/fibrillar
PrP106-126 was involved in both priming and activation of the
NLRP3 inflammasome (Figure 2) (Hafner-Bratkovic et al., 2012;
Shi et al., 2012). In line with previous studies, aggregated
PrP-peptide triggered NF-κB signaling, upregulating IL-1β
expression as well as other components necessary for NLRP3
assembly (Hafner-Bratkovic et al., 2012). NLRP3 inflammasome
activation and release of IL-1β in microglial cells was also
reported to Increase extracellular K+ levels, and phagocytosis
inhibition significantly attenuated PrP106-126-induced release of
IL-1β, through downregulation of NLRP3 expression (Hafner-
Bratkovic et al., 2012; Shi et al., 2012). PrP106-126 fibrils were
also found to increase ROS production in treated microglia
(Bacot et al., 2003; Yang et al., 2008). The ROS inhibitor,
N-acetyl-l-cysteine (NAC), significantly reduced IL-1β
production, and blocked NLRP3 and ASC upregulation after
exposure to PrP106-126 in murine microglia (Shi et al., 2012). In
a follow-up paper, these researchers found that the NLRP3
inflammasome complex negatively regulated TLR4-TRIF-
mediated autophagy by activating caspase-1-induced TRIF
cleavage in response to PrP106-126 stimulation (Lai et al.,
2018). As chronic inflammation is a common feature of
neurodegenerative diseases, the upregulation of autophagy by
inhibiting caspase-1 activation, with reduced neuroinflammation
and accelerated removal of misfolded protein, could be an
attractive therapeutic strategy for prion-induced insults (Lai
et al., 2018). This is consistent with the effect of Ka on
reducing NLRP3 inflammasome activation via upregulation of
autophagy in PD (Ahmed et al., 2020).
Despite the compelling in vitro data supporting the
involvement of NLRP3 in the pathogenesis of prion diseases, a
study by Nuvolone and colleagues showed that mice lacking
NLRP3 (Nlrp3−/−) or the inflammasome adaptor protein ASC
(Pycard−/−) succumbed to prion disease, with attack rates and
incubation times similar to wild-type mice following inoculation
with prions (strain RML) (Nuvolone et al., 2015). Levels of IL-1β
at end-stage disease were not affected by the absence of NLRP3 or
ASC proteins. This result does not directly contradict previous
studies highlighting the importance of NLRP3/ASC
inflammasome in the production of IL-1β (Agostini et al.,
2004; Strowig et al., 2012; Lamkanfi and Dixit, 2014), but does
allude to the existence of other potential caspase-1 independent
sources of IL-1β production, as seen in other disease phenotypes
(Fantuzzi et al., 1997; Cheng et al., 2008). Nuvolone et al., 2015
argue that the in vitro generated PrP fibrils are not infectious and
may trigger neurotoxicity by different pathways from those
activated in prion infections; however, the discrepancies
between these different groups may also be due to strain-
dependent variations in prion infection, as shown by a
number of different research groups, in both murine and
human prion diseases (Baker et al., 1999; Tixador et al., 2010;
Ayers et al., 2011).
Another factor which must also be considered is the influence
of a primed inflammatory response in the course of prion
diseases, whereby an underlying hyper-inflammatory state may
be enough of a trigger to alter the clinical trajectory of these
diseases. Interestingly, both Shi et al. (2012) and Hafner-
Bratkovic et al. (2012) primed the cells with LPS to mimic
chronic activation of microglia, as observed in prion diseases
(Hafner-Bratkovic et al., 2012; Shi et al., 2012). Hafner et al.
(2012) reported that while PrP-fibrils were able to activate NF-κB,
and increase IL-1βmRNA, this activation might not be sufficient
to produce prominent amounts of pro-IL-1β protein, but could
produce enough to induce a primed state, which might be easily
abrogated by bacterial infections or endogenous danger signals
(Combrinck et al., 2002). However, it could be argued that
infectious prions do not trigger inflammasome activation
without an underlying inflammatory trigger. Therapies
targeting the NLRP3 inflammasome shouldn’t be disregarded
for prion diseases, although more in vivo studies, using a variety
of infectious strains, are required to corroborate the in vitro data.
CONCLUSION
Neuroinflammation, and its link to the progression of
neurodegenerative disease, has been a key focus of research in
the past decade, in the hope that eventual breakthroughs in this area
will result in novel therapeutic approaches to treat these increasingly
prevalent diseases. Despite the diverse range of mechanisms
underlying these conditions, NLRP3 inflammasome activation
and dysregulation are common features of several
neurodegenerative diseases, both in the periphery and the CNS.
Given the presence of anNLRP3 inflammasome signature in several
neurodegenerative disorders, and that autoinflammatory diseases
are primarily driven byNLRP3 inflammasome activation (de Torre-
Minguela et al., 2017), it might be considered that these diseases are
autoinflammatory-like in nature and therefore could be placed on
the autoinflammatory immune spectrum (Peckham et al., 2017).
Although this review has focused on those inhibitors of the
NLRP3 inflammasome that have already been studied in various
neurodegenerative models, several other inhibitors are showing
promising results in other disease models as well as in clinical
trials. However, this topic is beyond the scope of this current
review and the reader is referred to Caseley et al., 2020, for a more
in-depth coverage (Caseley et al., 2020).
Several studies presented in this review have already shown
that modulating NLRP3 inflammasome expression and activation
inherent potential to delay the progression and impact of
neuroinflammation in a number of neurodegenerative disease
models, highlighting the importance of immune regulation.
Given these promising results, NLRP3 modulators warrant
further consideration for translation into clinical trials and
may prove to have a common therapeutic benefit across a
number of neurodegenerative disorders.
AUTHOR CONTRIBUTIONS
JH led the completion of the manuscript. MM acted as the
main supervisor and editor. HHJ-G, EC, SL-R, and JP all
contributed equally to the completion of the manuscript.
CHW-G and DP also edited and supervised the completion
of the manuscript.
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 6432549
Holbrook et al. Neurodegenerative Disease and the NLRP3 Inflammasome
FUNDING
The authors (EC, JP and MM) are supported by the EU Horizon
(2020) research and innovation program (ImmunAID; grant
agreement number 779295); HHJ-G, MM, and DP are
supported by grant SRC009, Cystic Fibrosis Trust; JH is
supported by the Cambridge Center for Parkinson-Plus and
The Cure Parkinson’s Trust; CHW-G is supported by a
RCUK/UKRI Research Innovation Fellowship awarded by the
Medical Research Council (MR/R007446/1); JH and CHW-G are
supported by the NIHR Cambridge Biomedical Research Center
Dementia and Neurodegeneration Theme (146281). (The views
expressed are those of the authors and not necessarily those of the
NHS, the NIHR or the Department of Health.)
REFERENCES
Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., et al.
(2015). NLRP3 inflammasome: from a danger signal sensor to a regulatory node
of oxidative stress and inflammatory diseases. Redox Biol. 4, 296–307. doi:10.
1016/j.redox.2015.01.008
Agostini, L., Martinon, F., Burns, K., Mcdermott, M. F., Hawkins, P. N., and
Tschopp, J. (2004). NALP3 forms an IL-1beta-processing inflammasome with
increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20,
319–325. doi:10.1016/s1074-7613(04)00046-9
Ahmed, S., Kwatra, M., Ranjan Panda, S., Murty, U. S. N., and Naidu, V. G. M.
(2020). Andrographolide suppresses NLRP3 inflammasome activation in
microglia through induction of parkin-mediated mitophagy in in-vitro and
in-vivomodels of Parkinson disease. Brain Behav. Immun. 91, 142–158. doi:10.
1016/j.bbi.2020.09.017
Alessi, D. R., and Sammler, E. (2018). LRRK2 kinase in Parkinson’s disease. Science
360, 36–37. doi:10.1126/science.aar5683
Amor, S., Puentes, F., Baker, D., and Van Der Valk, P. (2010). Inflammation in
neurodegenerative diseases. Immunology 129, 154–169. doi:10.1111/j.1365-
2567.2009.03225.x
Andersen, P. M. (2006). Amyotrophic lateral sclerosis associated with mutations in
the CuZn superoxide dismutase gene. Curr. Neurol. Neurosci. Rep. 6 (1), 37.
doi:10.1007/s11910-996-0008-9
Angeles, D. C., Gan, B. H., Onstead, L., Zhao, Y., Lim, K. L., Dachsel, J., et al. (2011).
Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating
oxidative stress-induced neuronal death. Hum. Mutat., 32 (12), 1390. doi:10.
1002/humu.21582
Antonyová, V., Kejík, Z., Brogyányi, T., Kaplánek, R., Pajková, M., Talianová, V.,
et al. (2020). Role of mtDNA disturbances in the pathogenesis of Alzheimer’s
and Parkinson’s disease. DNA Repair (Amst) 91–92, 102871. doi:10.1016/j.
dnarep.2020.102871
Ayers, J. I., Schutt, C. R., Shikiya, R. A., Aguzzi, A., Kincaid, A. E., and Bartz, J. C.
(2011). The strain-encoded relationship between PrP replication, stability and
processing in neurons is predictive of the incubation period of disease. PLoS
Pathog. 7, e1001317. doi:10.1371/journal.ppat.1001317
Bacot, S. M., Lenz, P., Frazier-Jessen, M. R., and Feldman, G. M. (2003). Activation
by prion peptide PrP106-126 induces a NF-kappaB-driven proinflammatory
response in human monocyte-derived dendritic cells. J. Leukoc. Biol. 74,
118–125. doi:10.1189/jlb.1102521
Baker, C. A., Lu, Z. Y., Zaitsev, I., and Manuelidis, L. (1999). Microglial activation
varies in different models of Creutzfeldt-Jakob disease. J. Virol. 73, 5089–5097.
doi:10.1128/JVI.73.6.5089-5097.1999
Bellezza, I., Grottelli, S., Costanzi, E., Scarpelli, P., Pigna, E., Morozzi, G., et al.
(2018). Peroxynitrite activates the NLRP3 inflammasome cascade in
SOD1(g93a) mouse model of amyotrophic lateral sclerosis. Mol. Neurobiol.
55 (3), 2350. doi:10.1007/s12035-017-0502-x
Beyer, M. M. S., Lonnemann, N., Remus, A., Latz, E., Heneka, M. T., and Korte, M.
(2020). Enduring changes in neuronal function upon systemic inflammation
are NLRP3 inflammasome dependent. J. Neurosci. 40 (28), 5480–5494. doi:10.
1523/jneurosci.0200-20.2020
Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., et al.
(2008). A novel pathogenic pathway of immune activation detectable before
clinical onset in Huntington’s disease. J. Exp. Med. 205, 1869–1877. doi:10.
1084/jem.20080178
Blennow, K., De Leon, M. J., and Zetterberg, H. (2006). Alzheimer’s disease. Lancet
368, 387–403. doi:10.1016/S0140-6736(06)69113-7
Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuntek, H., and Riederer, P.
(1995). Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal
fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci. Lett.
202, 17–20. doi:10.1016/0304-3940(95)12192-7
Bodar, E. J., Simon, A., De Visser, M., and Van Der Meer, J. W. (2009). Complete
remission of severe idiopathic cold urticaria on interleukin-1 receptor
antagonist (anakinra). Neth. J. Med. 67 (9), 302.
Bose, A., and Beal, M. F. (2016). Mitochondrial dysfunction in Parkinson’s disease.
J. Neurochem. 139 (Suppl. 1), 216. doi:10.1111/jnc.13731
Briner, A., Götz, J., and Polanco, J. C. (2020). Fyn kinase controls tau aggregation in
vivo. Cell Rep. 32, 108045. doi:10.1016/j.celrep.2020.108045
Budini, M., Buratti, E., Morselli, E., and Criollo, A. (2017). Autophagy and its
impact on neurodegenerative diseases: new roles for TDP-43 and C9orf72.
Front. Mol. Neurosci. 10, 170. doi:10.3389/fnmol.2017.00170
Caseley, E. A., Poulter, J. A., Rodrigues, F., and Mcdermott, M. F. (2020).
Inflammasome inhibition under physiological and pharmacological
conditions. Genes Immun. 21 (4), 211. doi:10.1038/s41435-020-0104-x
Chandra, S. R., Issac, T. G., Philip, M., and Gadad, V. (2016). Creutzfeldt-Jakob
disease phenotype and course: our experience from a tertiary center. Indian
J. Psychol. Med. 38, 438–442. doi:10.4103/0253-7176.191376
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., Van Der Brug, M.,
Cai, F., et al. (2017). A meta-analysis of genome-wide association studies
identifies 17 new Parkinson’s disease risk loci. Nat. Genet. 49, 1511–1516.
doi:10.1038/ng.3955
Chang, K., Wu, Y., Chen, Y., and Chen, C. (2015). Plasma inflammatory
biomarkers for Huntington’s disease patients and mouse model. Brain
Behav. Immun. 44, 121. doi:10.1016/j.bbi.2014.09.011
Chaudhuri, K. R., and Schapira, A. H. (2009). Non-motor symptoms of Parkinson’s
disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 8 (5),
464. doi:10.1016/S1474-4422(09)70068-7
Chen, D., Dixon, B. J., Doycheva, D. M., Li, B., Zhang, Y., Hu, Q., et al. (2018).
IRE1α inhibition decreased TXNIP/NLRP3 inflammasome activation through
miR-17-5p after neonatal hypoxic-ischemic brain injury in rats.
J. Neuroinflammation 15, (1), 32. doi:10.1186/s12974-018-1077-9
Cheng, W., Shivshankar, P., Li, Z., Chen, L., Yeh, I. T., and Zhong, G. (2008).
Caspase-1 contributes to Chlamydia trachomatis-induced upper urogenital
tract inflammatory pathologies without affecting the course of infection.
Infect. Immun. 76, 515–522. doi:10.1128/IAI.01064-07
Christgen, S., Place, D., and Kanneganti, T. (2020). Toward targeting
inflammasomes: insights into their regulation and activation. Cell Res. 30
(4), 315. doi:10.1038/s41422-020-0295-8
Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., et al.
(2013). Triggering of inflammasome by aggregated α–synuclein, an
inflammatory response in synucleinopathies. PLoS One 8, e55375. doi:10.
1371/journal.pone.0055375
Combrinck, M. I., Perry, V. H., and Cunningham, C. (2002). Peripheral infection
evokes exaggerated sickness behaviour in pre-clinical murine prion disease.
Neuroscience 112, 7–11. doi:10.1016/s0306-4522(02)00030-1
Craft, J. M., Watterson, D. M., Hirsch, E., and Van Eldik, L. J. (2005). Interleukin 1
receptor antagonist knockout mice show enhanced microglial activation and
neuronal damage induced by intracerebroventricular infusion of human beta-
amyloid. J. Neuroinflammation 2, 15. doi:10.1186/1742-2094-2-15
Crotti, A., and Glass, C. K. (2015). The choreography of neuroinflammation in
Huntington’s disease. Trends Immunol. 36, 364–373. doi:10.1016/j.it.2015.
04.007
Cunha, C., Santos, C., Gomes, C., Fernandes, A., Correia, A. M., Sebastião, A. M.,
et al. (2018). Downregulated glia interplay and increased miRNA-155 as
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 64325410
Holbrook et al. Neurodegenerative Disease and the NLRP3 Inflammasome
promising markers to track ALS at an early stage. Mol. Neurobiol. 55,
4207–4224. doi:10.1007/s12035-017-0631-2
Daniels, M. J., Rivers-Auty, J., Schilling, T., Spencer, N. G., Watremez, W.,
Fasolino, V., et al. (2016). Fenamate NSAIDs inhibit the NLRP3
inflammasome and protect against Alzheimer’s disease in rodent models.
Nat. Commun. 7, 12504. doi:10.1038/ncomms12504
Davis, S. A., Gan, K. A., Dowell, J. A., Cairns, N. J., and Gitcho, M. A. (2017). TDP-
43 expression influences amyloidβ plaque deposition and tau aggregation.
Neurobiol. Dis. 103, 154–162. doi:10.1016/j.nbd.2017.04.012
De Biase, D., Piegari, G., Prisco, F., Cimmino, I., Pirozz, I. C., Mattac Raso, G.,
et al. (2020). Autophagy and NLRP3 inflammasome crosstalk in
neuroinflammation in aged bovine brains. J. Cell. Physiol. 235, 5394–5403.
doi:10.1002/jcp.29426
de Jong, S., Huisman, M., Sutedja, N., Van Der Kooi, A., De Visser, M., Schelhaas,
J., et al. (2013). Endogenous female reproductive hormones and the risk of
amyotrophic lateral sclerosis. J. Neurol. 260 (2), 507. doi:10.1007/s00415-012-
6665-5
De Strooper, B., and Karran, E. (2016). The cellular phase of Alzheimer’s disease.
Cell 164, 603–615. doi:10.1016/j.cell.2015.12.056
de Torre-Minguela, C., Mesa Dl Castillo, P., and Pelegrín, P. (2017). The NLRP3
and pyrin inflammasomes: implications in the pathophysiology of
autoinflammatory diseases. Front. Immunol. 8, 43. doi:10.3389/fimmu.2017.
00043
Debye, B., Schmülling, L., Zhou, L., Rune, G., Beyer, C., and Johann, S. (2018).
Neurodegeneration and NLRP3 inflammasome expression in the anterior
thalamus of SOD1(G93A) ALS mice. Brain Pathol. 28 (1), 14–27. doi:10.
1111/bpa.12467
Dempsey, C., Rubio Araiz, A., Bryson, K. J., Finucane, O., Larkin, C., Mills, E. L.,
et al. (2017). Inhibiting the NLRP3 inflammasome with MCC950 promotes
non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1
mice. Brain Behav. Immun. 61, 306–316. doi:10.1016/j.bbi.2016.12.014
Deora, V., Lee, J. D., Albornoz, E. A., Mcalary, L., Jagaraj, C. J., Robertson, A. A. B.,
et al. (2020). The microglial NLRP3 inflammasome is activated by amyotrophic
lateral sclerosis proteins. Glia 68 (2), 407. doi:10.1002/glia.23728
Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., et al.
(2013). Colonic inflammation in Parkinson’s disease. Neurobiol. Dis. 50, 42.
doi:10.1016/j.nbd.2012.09.007
DiCarlo, G., Wilcock, D., Henderson, D., Gordon, M., and Morgan, D. (2001).
Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic
mice. Neurobiol. Aging 22, 1007–1012. doi:10.1016/s0197-4580(01)00292-5
Duennwald, M., and Lindquist, S. (2008). Impaired ERAD and ER stress are early
and specific events in polyglutamine toxicity. Genes Dev. 22 (23), 3308. doi:10.
1101/gad.1673408
Dugger, B. N., and Dickson, D. W. (2017). Pathology of neurodegenerative
diseases. Cold Spring Harb Perspect. Biol. 9 (7), a028035. doi:10.1101/
cshperspect.a028035
Edwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E. H., Beecham, G. W.,
et al. (2010). Genome-wide association study confirms SNPs in SNCA and the
MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet.
74, 97–109. doi:10.1111/j.1469-1809.2009.00560.x
Elliott, E. I., Miller, A. N., Banoth, B., Iyer, S. S., Stotland, A., Weiss, J. P., et al.
(2018). Mitochondrial assembly of the NLRP3 inflammasome complex is
initiated at priming. J. Immunol. 200, 3047–3052. doi:10.4049/jimmunol.
1701723
Fan, Z., Pan, Y. T., Zhang, Z. Y., Yang, H., Yu, S. Y., Zheng, Y., et al. (2020).
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are
correlated with motor severity and progression in Parkinson’s disease.
J. Neuroinflammation 17 (1), 11. doi:10.1186/s12974-019-1670-6
Fantuzzi, G., Ku, G., Harding, M. W., Livingston, D. J., Sipe, J. D., Kuida, K., et al.
(1997). Response to local inflammation of IL-1 beta-converting enzyme-
deficient mice. J. Immunol. 158, 1818–1824.
Feng, Y., Tan, Z., Wu, L., Dong, F., and Zhang, F. (2020). The involvement of
NLRP3 inflammasome in the treatment of Alzheimer’s disease. Ageing Res. Rev.
64, 101192. doi:10.1016/j.arr.2020.101192
Fiala, M., Liu, Q. N., Sayre, J., Pop, V., Brahmandam, V., Graves, M. C., et al. (2002).
Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer’s disease brain
and damage the blood-brain barrier. Eur. J. Clin. Invest. 32 (5), 360. doi:10.
1046/j.1365-2362.2002.00994.x
Fink, S. L., and Cookson, B. T. (2006). Caspase-1-dependent pore formation during
pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 8
(11), 1812. doi:10.1111/j.1462-5822.2006.00751.x
Flores, J., Noel, A., Foveau, B., Lynham, J., Lecrux, C., and Leblanc, A. C. (2018).
Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an
Alzheimer’s disease mouse model. Nat. Commun. 9, 3916. doi:10.1038/s41467-
018-06449-x
Frandemiche, M. L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., et al.
(2014). Activity-dependent tau protein translocation to excitatory synapse is
disrupted by exposure to amyloid-beta oligomers. J. Neurosci. 34, 6084–6097.
doi:10.1523/JNEUROSCI.4261-13.2014
Friedlander, R. M., Brown, R. H., Gagliardini, V., Wang, J., and Yuan, J. (1997).
Inhibition of ICE slows ALS in mice. Nature 388 (6637), 31. doi:10.1038/40299
Gao, H. M., and Hong, J. S. (2008). Why neurodegenerative diseases are
progressive: uncontrolled inflammation drives disease progression. Trends
Immunol. 29, 357–365. doi:10.1016/j.it.2008.05.002
Gao, J., Wang, L., Huntley, M. L., Perry, G., and Wang, X. (2018).
Pathomechanisms of TDP-43 in neurodegeneration. J. Neurochem. doi:10.
1111/jnc.14327
GBD (2019). Global, regional, and national burden of neurological disorders,
1990–2016: a systematic analysis for the global burden of disease study 2016.
Lancet Neurol. 18, 459–480. doi:10.1016/S1474-4422(18)30499-X
Ghasemi, M., and Brown, R. H. (2018). Genetics of amyotrophic lateral sclerosis.
Cold Spring Harbor Perspect. Med. 8 (5), 217–226. doi:10.1101/cshperspect.
a024125
Ghosh, S., Wu, M. D., Shaftel, S. S., Kyrkanides, S., Laferla, F. M., Olschowka, J. A.,
et al. (2013). Sustained interleukin-1beta overexpression exacerbates tau
pathology despite reduced amyloid burden in an Alzheimer’s mouse model.
J. Neurosci. 33, 5053–5064. doi:10.1523/JNEUROSCI.4361-12.2013
Giese, A., Groschup, M. H., Hess, B., and Kretzschmar, H. A. (1995). Neuronal cell
death in scrapie-infected mice is due to apoptosis. Brain Pathol. 5, 213–221.
doi:10.1111/j.1750-3639.1995.tb00597.x
Glinsky, G. (2008). SNP-guided microRNA maps (MirMaps) of 16 common
human disorders identify a clinically accessible therapy reversing
transcriptional aberrations of nuclear import and inflammasome pathways.
Cell Cycle 7 (22), 3564. doi:10.4161/cc.7.22.7073
Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani,
S., et al. (2018). Inflammasome inhibition prevents α-synuclein pathology and
dopaminergic neurodegeneration in mice. Sci Transl. Med. 10 (465), eaah4066.
doi:10.1126/scitranslmed.aah4066
Gray, F., Adle-Biassette, H., Chretien, F., Ereau, T., Delisle, M. B., and Vital, C.
(1999a). [Neuronal apoptosis in human prion diseases]. Bull. Acad. Natl. Med.
183, 305–320. discussion 320-301.
Gray, F., Chretien, F., Adle-Biassette, H., Dorandeu, A., Ereau, T., Delisle, M. B.,
et al. (1999b). Neuronal apoptosis in Creutzfeldt-Jakob disease. J. Neuropathol.
Exp. Neurol. 58, 321–328. doi:10.1097/00005072-199904000-00002
Griffin, W. S., Stanley, L. C., Ling, C., White, L., Macleod, V., Perrot, L. J., et al.
(1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down
syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 86, 7611–7615.
doi:10.1073/pnas.86.19.7611
Gugliandolo, A., Giacoppo, S., Bramanti, P., and Mazzon, E. (2018). NLRP3
inflammasome activation in a transgenic amyotrophic lateral sclerosis
model. Inflammation 41 (1), 93. doi:10.1007/s10753-017-0667-5
Hafner-Bratkovic, I., Bencina, M., Fitzgerald, K. A., Golenbock, D., and Jerala, R.
(2012). NLRP3 inflammasome activation in macrophage cell lines by prion
protein fibrils as the source of IL-1beta and neuronal toxicity. Cell Mol. Life Sci.
69, 4215–4228. doi:10.1007/s00018-012-1140-0
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T.,
et al. (2008). The NALP3 inflammasome is involved in the innate immune
response to amyloid-beta. Nat. Immunol. 9, 857–865. doi:10.1038/ni.1636
Hamza, T. H., Zabetian, C. P., Tenesa, A., Laederach, A., Montimurro, J., Yearout,
D., et al. (2010). Common genetic variation in the HLA region is associated with
late-onset sporadic Parkinson’s disease. Nat. Genet. 42, 781–785. doi:10.1038/
ng.642
Han, X., Sun, S., Sun, Y., Song, Q., Zhu, J., Song, N., et al. (2019). Small molecule-
driven NLRP3 inflammation inhibition via interplay between ubiquitination
and autophagy: implications for Parkinson disease. Autophagy 15, 1860–1881.
doi:10.1080/15548627.2019.1596481
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 64325411
Holbrook et al. Neurodegenerative Disease and the NLRP3 Inflammasome
Haque, M. E., Akther, M., Jakaria, M., Kim, I. S., Azam, S., and Choi, D. K. (2020).
Targeting the microglial NLRP3 inflammasome and its role in Parkinson’s
disease. Movement Disord. 35 (1), 20–33. doi:10.1002/mds.27874
Harrison, O. J., Srinivasan, N., Pott, J., Schiering, C., Krausgruber, T., Ilott, N. E.,
et al. (2015). Epithelial-derived IL-18 regulates Th17 cell differentiation and
Foxp3(+) Treg cell function in the intestine. Mucosal Immunol. 8, 1226–1236.
doi:10.1038/mi.2015.13
Heitzer, M., Kaiser, S., Kanagaratnam, M., Zendedel, A., Hartmann, P., Beyer, C.,
et al. (2017). Administration of 17β-estradiol improves motoneuron survival
and down-regulates inflammasome activation in male SOD1(g93aG93A) ALS
mice. Mol. Neurobiol. 54 (10), 8429. doi:10.1007/s12035-016-0322-4
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker,
A., et al. (2013). NLRP3 is activated in Alzheimer’s disease and contributes to
pathology in APP/PS1 mice. Nature 493, 674–678. doi:10.1038/nature11729
Herber, D. L., Roth, L. M., Wilson, D., Wilson, N., Mason, J. E., Morgan, D., et al.
(2004). Time-dependent reduction in Abeta levels after intracranial LPS
administration in APP transgenic mice. Exp. Neurol. 190, 245–253. doi:10.
1016/j.expneurol.2004.07.007
Herman, A. M., Khandelwal, P. J., Rebeck, G. W., and Moussa, C. E. (2012). Wild
type TDP-43 induces neuro-inflammation and alters APP metabolism in
lentiviral gene transfer models. Exp. Neurol. 235, 297–305. doi:10.1016/j.
expneurol.2012.02.011
Iłzecka, J., Stelmasiak, Z., and Dobosz, B. (2001). Interleukin-1beta converting
enzyme/caspase-1 (ICE/caspase-1) and soluble APO-1/Fas/CD 95 receptor in
amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 103 (4), 255. doi:10.
1034/j.1600-0404.2001.103004255.x
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., and
Hashizume, Y. (2003). Distribution of major histocompatibility complex
class II-positive microglia and cytokine profile of Parkinson’s disease brains.
Acta Neuropathol. 106 (6), 518. doi:10.1007/s00401-003-0766-2
Ising, C., and Heneka, M. T. (2018). Functional and structural damage of neurons
by innate immune mechanisms during neurodegeneration. Cell Death Dis. 9,
120. doi:10.1038/s41419-017-0153-x
Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A.,
et al. (2019). NLRP3 inflammasome activation drives tau pathology. Nature
575, 669–673. doi:10.1038/s41586-019-1769-z
Italiani, P., Carlesi, C., Giungato, P., Puxeddu, I., Borroni, B., Bossù, P., et al. (2014).
Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic
lateral sclerosis. J. Neuroinflammation 11, 94. doi:10.1186/1742-2094-11-94
Izumikawa, K., Nobe, Y., Yoshikawa, H., Ishikawa, H., Miura, Y., et al. (2017).
TDP-43 stabilises the processing intermediates of mitochondrial transcripts.
Sci. Rep. 7, 7709. doi:10.1038/s41598-017-06953-y
Jin, X., and Yamashita, T. (2016). Microglia in central nervous system repair after
injury. J. Biochem. 159 (5), 491. doi:10.1093/jb/mvw009
Johann, S., Heitzer, M., Kanagaratnam, M., Goswami, A., Rizo, T., Weis, J., et al.
(2015). NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse
model of ALS and in human sporadic ALS patients. Glia 63 (12), 2260. doi:10.
1002/glia.22891
Kadhim, H., Deltenre, P., Martin, J. J., and Sébire, G. (2016). In-situ expression of
Interleukin-18 and associated mediators in the human brain of sALS patients:
hypothesis for a role for immune-inflammatory mechanisms. Med. Hypotheses
86, 14. doi:10.1016/j.mehy.2015.11.022
Kalathur, R. K. R., Giner-Lamia, J., Machado, S., Barata, T., Ayasolla, K. R. S., and
Futschik, M. E. (2015). The unfolded protein response and its potential role in
Huntington’s disease elucidated by a systems biology approach. F1000Res 4,
103. doi:10.12688/f1000research.6358.2
Kalia, L. V., and Lang, A. E. (2015). Parkinson’s disease. Lancet 386, 896–912.
doi:10.1016/S0140-6736(14)61393-3
Kelley, N., Jeltema, D., Duan, Y., and He, Y. (2019). The NLRP3 inflammasome: an
overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 20 (13),
3328. doi:10.3390/ijms20133328
Kempuraj, D., Thangavel, R., Natteru, P. A., Selvakumar, G. P., Saeed, D., Zahoor,
H., et al. (2016). Neuroinflammation induces neurodegeneration. J. Neurol.
Neurosurg. Spine 1, 1003.
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S.,
et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile
parkinsonism. Nature 392, 605–608. doi:10.1038/33416
Kouli, A., Camacho, M., Allinson, K., and Williams-Gray, C. H. (2020).
Neuroinflammation and protein pathology in Parkinson’s disease dementia.
Acta Neuropathol. Commun. 8 (1), 211. doi:10.1186/s40478-020-01083-5
LaClair, K. D., Donde, A., Ling, J. P., Jeong, Y. H., Chhabra, R., Martin, L. J., et al.
(2016). Depletion of TDP-43 decreases fibril and plaque β-amyloid and
exacerbates neurodegeneration in an Alzheimer’s mouse model. Acta
Neuropathol. 132, 859–873. doi:10.1007/s00401-016-1637-y
Lai, M., Yao, H., Shah, S. Z. A., Wu, W., Wang, D., Zhao, Y., et al. (2018). The
NLRP3-caspase 1 inflammasome negatively regulates autophagy via TLR4-
TRIF in prion peptide-infected microglia. Front. Aging Neurosci. 10, 116. doi:10.
3389/fnagi.2018.00116
Lamkanfi, M., and Dixit, V. M. (2014). Mechanisms and functions of
inflammasomes. Cell 157, 1013–1022. doi:10.1016/j.cell.2014.04.007
Larson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D.
A., et al. (2012). The complex PrP(c)-Fyn couples human oligomeric Aβ with
pathological tau changes in Alzheimer’s disease. J. Neurosci. 32, 16857–16871a.
doi:10.1523/JNEUROSCI.1858-12.2012
Lee, E., Hwang, I., Park, S., Hong, S., Hwang, B., Cho, Y., et al. (2019). MPTP-
driven NLRP3 inflammasome activation in microglia plays a central role in
dopaminergic neurodegeneration. Cell Death Differ. 26, 213–228. doi:10.1038/
s41418-018-0124-5
Lee, G., Thangavel, R., Sharma, V. M., Litersky, J. M., Bhaskar, K., Fang, S. M., et al.
(2004). Phosphorylation of tau by fyn: implications for Alzheimer’s disease.
J. Neurosci. 24, 2304–2312. doi:10.1523/JNEUROSCI.4162-03.2004
Lee, J. Y., Lee, J. D., Phipps, S., Noakes, P. G., andWoodruff, T. M. (2015). Absence
of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse
model of amyotrophic lateral sclerosis. J. Neuroinflammation 12, 90. doi:10.
1186/s12974-015-0310-z
Leitman, J., Ulrich Hartl, F., and Lederkremer, G. (2013). Soluble forms of polyQ-
expanded huntingtin rather than large aggregates cause endoplasmic reticulum
stress. Nat. Commun. 4, 2753. doi:10.1038/ncomms3753
Lerner, A. G., Upton, J. P., Praveen, P., Ghosh, R., Nakagawa, Y., Igbaria, A., et al.
(2012). IRE1α induces thioredoxin-interacting protein to activate the NLRP3
inflammasome and promote programmed cell death during endoplasmic
reticulum stress. Cell Metab. 16, 250–264. doi:10.1016/j.cmet.2012.07.007
Li, M., Ona, V. O., Guégan, C., Chen, M., Jackson-Lewis, V., Andrews, L. J., et al.
(2000). Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse
model. Science 288 (5464), 335. doi:10.1126/science.288.5464.335
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J.,
Schirmer, L., et al. (2017). Neurotoxic reactive astrocytes are induced by
activated microglia. Nature 541 (7638), 481. doi:10.1038/nature21029
Liston, A., and Masters, S. L. (2017). Homeostasis-altering molecular processes as
mechanisms of inflammasome activation. Nat. Rev. Immunol. 17 (3), 208.
doi:10.1038/nri.2016.151
Liu, J., and Wang, F. (2017). Role of neuroinflammation in amyotrophic lateral
sclerosis: cellular mechanisms and therapeutic implications. Front. Immunol. 8,
1005. doi:10.3389/fimmu.2017.01005
Llanos-González, E., Henares-Chavarino, Á. A., Pedrero-Prieto, C. M., García-
Carpintero, S., Frontiñán-Rubio, J., Sancho-Bielsa, F. J., et al. (2020). Interplay
between mitochondrial oxidative disorders and proteostasis in Alzheimer’s
disease. Front. Neurosci. 13, 1444. doi:10.3389/fnins.2019.01444
Louveau, A., Harris, T. H., and Kipnis, J. (2015). Revisiting the mechanisms of CNS
immune privilege. Trends Immunol. 36 (10), 569. doi:10.1016/j.it.2015.08.006
Lu, A., Magupalli, V. G., Ruan, J., Yin, Q., Atianand, M. K., Vos, M. R., et al. (2014).
Unified polymerization mechanism for the assembly of ASC-dependent
inflammasomes. Cell 156, 1193–2206. doi:10.1016/j.cell.2014.02.008
Maier, A., Deigendesch, N., Müller, K., Weishaupt, J. H., Krannich, A., Röhle, R.,
et al. (2015). Interleukin-1 antagonist anakinra in amyotrophic lateral
sclerosis--A pilot study. PLoS One 10 (10), e0139684. doi:10.1371/journal.
pone.0139684
Marchetti, C., Swartzwelter, B., Gamboni, F., Neff, C. P., Richter, K., Azam, T., et al.
(2018). OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the
NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc.
Natl. Acad. Sci. U.S.A. 115, E1530–E1539. doi:10.1073/pnas.1716095115
Martinon, F., Burns, K., and Tschopp, J. (2002). The inflammasome: a molecular
platform triggering activation of inflammatory caspases and processing of
proIL-beta. Mol. Cell 10, 417–426. doi:10.1016/s1097-2765(02)00599-3
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 64325412
Holbrook et al. Neurodegenerative Disease and the NLRP3 Inflammasome
Massano, J., and Bhatia, K. P. (2012). Clinical approach to Parkinson’s disease:
features, diagnosis, and principles of management. Cold Spring Harb Perspect.
Med. 2 (6), a008870. doi:10.1101/cshperspect.a008870
Matheoud, D., Sugiura, A., Bellemare-Pelletier, A., Laplante, A., Rondeau, C.,
Chemali, M., et al. (2016). Parkinson’s disease-related proteins PINK1 and
parkin repress mitochondrial antigen presentation. Cell 166 (2), 314. doi:10.
1016/j.cell.2016.05.039
McGeer, P. L., Itagaki, S., Boyes, B. E., and Mcgeer, E. G. (1988). Reactive microglia
are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s
disease brains. Neurology 38 (8), 1285. doi:10.1212/wnl.38.8.1285
Meissner, F., Molawi, K., and Zychlinsky, A. (2010). Mutant superoxide dismutase
1-induced IL-1beta accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. U.S.A.
107 (29), 13046. doi:10.1073/pnas.1002396107
Menu, P., Mayor, A., Zhou, R., Tardivel, A., Ichijo, H., Mori, K., et al. (2012). ER
stress activates the NLRP3 inflammasome via an UPR-independent pathway.
Cell Death Dis. 3, e261. doi:10.1038/cddis.2011.132
Morrice, J. R., Gregory-Evans, C. Y., and Shaw, C. A. (2018). Animal models of
amyotrophic lateral sclerosis: a comparison of model validity. Neural Regen.
Res. 13 (12), 2050. doi:10.4103/1673-5374.241445
Motta, M., Imbesi, R., Di Rosa, M., Stivala, F., andMalaguarnera, L. (2007). Altered
plasma cytokine levels in Alzheimer’s disease: correlation with the disease
progression. Immunol. Lett. 114 (1), 46. doi:10.1016/j.imlet.2007.09.002
Nalls, M. A., Pankratz, N., Lill, C. M., Do, C. B., Hernandez, D. G., Saad, M., et al.
(2014). Large-scale meta-analysis of genome-wide association data identifies six
new risk loci for Parkinson’s disease. Nat. Genet. 46, 989–993. doi:10.1038/ng.
3043
Nuvolone, M., Sorce, S., Schwarz, P., and Aguzzi, A. (2015). Prion pathogenesis in
the absence of NLRP3/ASC inflammasomes. PLoS One 10, e0117208. doi:10.
1371/journal.pone.0117208
Nygaard, H. B. (2018). Targeting fyn kinase in Alzheimer’s disease. Biol. Psychiatry
83, 369–376. doi:10.1016/j.biopsych.2017.06.004
Ojala, J. O., Sutinen, E. M., Salminen, A., and Pirttila, T. (2008). Interleukin-18
increases expression of kinases involved in tau phosphorylation in SH-SY5Y
neuroblastoma cells. J. Neuroimmunol 205, 86–93. doi:10.1016/j.jneuroim.
2008.09.012
Oslowski, C. M., Hara, T., O’sullivan-Murphy, B., Kanekura, K., Lu, S., Hara, M.,
et al. (2012). Thioredoxin-interacting protein mediates ER stress-induced beta
cell death through initiation of the inflammasome. Cell Metab. 16, 265–273.
doi:10.1016/j.cmet.2012.07.005
Ou, Z., Zhou, Y., Wang, L., Xue, L., Zheng, J., Chen, L., et al. (2020). NLRP3
inflammasome inhibition prevents α-synuclein pathology by relieving
autophagy dysfunction in chronic MPTP-treated NLRP3 knockout mice.
Mol. Neurobiol. doi:10.1007/s12035-020-02198-5
Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M., and Kwakowsky, A. (2019). The
role of microglia and astrocytes in Huntington’s disease. Front. Mol. Neurosci.
12, 258. doi:10.3389/fnmol.2019.00258
Panicker, N., Sarkar, S., Harischandra, D. S., Neal, M., Kam, T. I., Jin, H., et al.
(2019). Fyn kinase regulates misfolded α-synuclein uptake and NLRP3
inflammasome activation in microglia. J. Exp. Med. 216, 1411–1430. doi:10.
1084/jem.20182191
Pankratz, N., Wilk, J. B., Latourelle, J. C., Destefano, A. L., Halter, C., Pugh, E. W.,
et al. (2009). Genomewide association study for susceptibility genes
contributing to familial Parkinson disease. Hum. Genet. 124, 593–605.
doi:10.1007/s00439-008-0582-9
Park, S., Sapkota, K., Kim, S., and Kim, H. (2011). Kaempferol acts through
mitogen-activated protein kinases and protein kinase B/AKT to elicit protection
in a model of neuroinflammation in BV2 microglial cells. Br. J. Pharmacol. 164,
1008–1025. doi:10.1111/j.1476-5381.2011.01389.x
Peckham, D., Scambler, T., Savic, S., and Mcdermott, M. F. (2017). The burgeoning
field of innate immune-mediated disease and autoinflammation. J. Pathol. 241,
123–139. doi:10.1002/path.4812
Pellegrini, C., Antonioli, L., Calderone, V., Colucci, R., Fornai, M., and Blandizzi, C.
(2020). Microbiota-gut-brain axis in health and disease: is NLRP3
inflammasome at the crossroads of microbiota-gut-brain communications?
Prog. Neurobiol. 191, 101806. doi:10.1016/j.pneurobio.2020.101806
Pfeiffer, R. F. (2016). Non-motor symptoms in Parkinson’s disease. Parkinsonism
Relat. Disord. 22 (Suppl. 1), S119. doi:10.1016/j.parkreldis.2015.09.004
Philips, T., and Rothstein, J. D. (2015). Rodent models of amyotrophic lateral
sclerosis. Curr. Protoc. Pharmacol. 69, 5. doi:10.1002/0471141755.ph0567s69
Pierce, S., and Coetzee, G. A. (2017). Parkinson’s disease-associated genetic
variation is linked to quantitative expression of inflammatory genes. PLoS
One 12 (4), e0175882. doi:10.1371/journal.pone.0175882
Politis, M., Lahiri, N., Niccolini, F., Su, P., Wu, K., Giannetti, P., et al. (2015).
Increased central microglial activation associated with peripheral cytokine
levels in premanifest Huntington’s disease gene carriers. Neurobiol. Dis. 83,
115. doi:10.1016/j.nbd.2015.08.011
Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A., and Patel, B. K. (2019).
Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic
lateral sclerosis. Front. Mol. Neurosci. 12, 25. doi:10.3389/fnmol.2019.00025
Prusiner, S. B. (1998). The prion diseases. Brain Pathol. 8, 499–513.
Rocha, N. P., Ribeiro, F. M., Furr-Stimming, E., and Teixeira, A. L. (2016).
Neuroimmunology of huntington’s disease: revisiting evidence from
human studies. Mediators Inflamm. 2016, 8653132. doi:10.1155/2016/
8653132
Rodrigues, F. B., Byrne, L. M., Mccolgan, P., Robertson, N., Tabrizi, S. J., Zetterberg,
H., et al. (2016). Cerebrospinal fluid inflammatory biomarkers reflect clinical
severity in Huntington’s disease. PLoS One 11 (9), e0163479. doi:10.1371/
journal.pone.0163479
Rushworth, J. V., Griffiths, H. H., Watt, N. T., and Hooper, N. M. (2013). Prion
protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the
transmembrane LRP1. J. Biol. Chem. 288, 8935–8951. doi:10.1074/jbc.M112.
400358
Sánchez-López, F., I, T., Agüera, E., Feijóo, M., Fernández-Bolaños, R., Sánchez, F.,
et al. (2012). Oxidative stress and inflammation biomarkers in the blood of
patients with Huntington’s disease. Neurol. Res. 34 (7), 721. doi:10.1179/
1743132812Y.0000000073
Saiki, M., Baker, A., Williams-Gray, C. H., Foltynie, T., Goodman, R. S., Taylor, C.
J., et al. (2010). Association of the human leucocyte antigen region with
susceptibility to Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 81 (8),
890. doi:10.1136/jnnp.2008.162883
Sapp, E., Kegel, K., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., et al.
(2001). Early and progressive accumulation of reactive microglia in the
Huntington disease brain. J. Neuropathol. Exp. Neurol. 60 (2), 161. doi:10.
1093/jnen/60.2.161
Saresella, M., La Rosa, F., Piancone, F., Zoppis, M., Marventano, I., Calabrese, E.,
et al. (2016). The NLRP3 and NLRP1 inflammasomes are activated in
Alzheimer’s disease. Mol. Neurodegener. 11, 23. doi:10.1186/s13024-016-
0088-1
Sarkar, S., Malovic, E., Harishchandra, D. S., Ghaisas, S., Panicker, N., Charli, A.,
et al. (2017). Mitochondrial impairment in microglia Amplifies NLRP3
inflammasome proinflammatory signaling in cell culture and animal models
of Parkinson’s disease. NPJ Parkinson’s Dis. 3, 30. doi:10.1038/s41531-017-
0032-2
Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., et al. (2009).
Genome-wide association study identifies common variants at four loci as
genetic risk factors for Parkinson’s disease. Nat. Genet. 41 (12), 1303. doi:10.
1038/ng.485
Schmidt, R. L., and Lenz, L. L. (2012). Distinct licensing of IL-18 and IL-1β
secretion in response to NLRP3 inflammasome activation. PLoS One 7 (9),
e45186. doi:10.1371/journal.pone.0045186
Schonhoff, A. M., Williams, G. P., Wallen, Z. D., Standaert, D. G., and Harms, A. S.
(2020). Innate and adaptive immune responses in Parkinson’s disease. Prog.
Brain Res. 252, 169. doi:10.1016/bs.pbr.2019.10.006
Scott, K. M., Kouli, A., Yeoh, S. L., Clatworthy, M. R., and Williams-Gray, C. H.
(2018). A systematic review and meta-analysis of Alpha synuclein auto-
antibodies in Parkinson’s disease. Front. Neurol. 9, 815. doi:10.3389/fneur.
2018.00815
Shaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J. N., Johnson, R. E., and
O’banion, M. K. (2007). Sustained hippocampal IL-1 beta overexpression
mediates chronic neuroinflammation and ameliorates Alzheimer plaque
pathology. J. Clin. Invest. 117, 1595–1604. doi:10.1172/JCI31450
Sharief, M. K., Green, A., Dick, J. P., Gawler, J., and Thompson, E. J. (1999).
Heightened intrathecal release of proinflammatory cytokines in Creutzfeldt-
Jakob disease. Neurology 52, 1289–1291. doi:10.1212/wnl.52.6.1289
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 64325413
Holbrook et al. Neurodegenerative Disease and the NLRP3 Inflammasome
Sheng, J. G., Ito, K., Skinner, R. D., Mrak, R. E., Rovnaghi, C. R., Van Eldik, L. J.,
et al. (1996). In vivo and in vitro evidence supporting a role for the
inflammatory cytokine interleukin-1 as a driving force in Alzheimer
pathogenesis. Neurobiol. Aging 17, 761–766. doi:10.1016/0197-4580(96)
00104-2
Shi, F., Yang, L., Kouadir, M., Yang, Y., Wang, J., Zhou, X., et al. (2012). The
NALP3 inflammasome is involved in neurotoxic prion peptide-induced
microglial activation. J. Neuroinflammation 9, 73. doi:10.1186/1742-2094-9-73
Siew, J. J., Chen, H. M., Chen, H. Y., Chen, H. L., Chen, C. M., Soong, B. W., et al.
(2019). Galectin-3 is required for the microglia-mediated brain inflammation in
a model of Huntington’s disease. Nat. Commun. 10, 3473. doi:10.1038/s41467-
019-11441-0
Silvestroni, A., Faull, R., Strand, A., and Möller, T. (2009). Distinct
neuroinflammatory profile in post-mortem human Huntington’s disease.
Neuroreport 20 (12), 1098. doi:10.1097/WNR.0b013e32832e34ee
Simard, A. R., Soulet, D., Gowing, G., Julien, J. P., and Rivest, S. (2006). Bone
marrow-derived microglia play a critical role in restricting senile plaque
formation in Alzheimer’s disease. Neuron 49, 489–502. doi:10.1016/j.neuron.
2006.01.022
Simon-Sanchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., et al.
(2009). Genome-Wide Association Study reveals genetic risk underlying
Parkinson’s disease. Nat. Genet. 41, 1308–1312. doi:10.1038/ng.487
Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative
diseases. Nat. Rev. Neurosci. 4 (1), 49. doi:10.1038/nrn1007
Soulet, D., and Cicchetti, F. (2011). The role of immunity in Huntington’s disease.
Mol. Psychiatry 16 (9), 889. doi:10.1038/mp.2011.28
Stancu, I. C., Cremers, N., Vanrusselt, H., Couturier, J., Vanoosthuyse, A., Kessels,
S., et al. (2019). Aggregated Tau activates NLRP3-ASC inflammasome
exacerbating exogenously seeded and non-exogenously seeded Tau
pathology in vivo. Acta Neuropathol. 137, 599–617. doi:10.1007/s00401-018-
01957-y
Stoeck, K., Bodemer, M., and Zerr, I. (2006). Pro- and anti-inflammatory cytokines
in the CSF of patients with Creutzfeldt-Jakob disease. J. Neuroimmunol 172,
175–181. doi:10.1016/j.jneuroim.2005.10.008
Stoeck, K., Schmitz, M., Ebert, E., Schmidt, C., and Zerr, I. (2014). Immune
responses in rapidly progressive dementia: a comparative study of
neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer’s
disease and multiple sclerosis. J. Neuroinflammation 11, 170. doi:10.1186/
s12974-014-0170-y
Strowig, T., Henao-Mejia, J., Elinav, E., and Flavell, R. (2012). Inflammasomes in
health and disease. Nature 481, 278–286. doi:10.1038/nature10759
Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., et al.
(2017). T cells from patients with Parkinson’s disease recognize α-synuclein
peptides. Nature 546 (7660), 292. doi:10.1038/nature23896
Tan, E. K., Chao, Y. X., West, A., Chan, L. L., Poewe, W., and Jankovic, J. (2020).
Parkinson disease and the immune system - associations, mechanisms and
therapeutics. Nat. Rev. Neurol. 16 (6), 303. doi:10.1038/s41582-020-0344-4
Thal, D. R., Rüb, U., Orantes, M., and Braak, H. (2002). Phases of A beta-deposition
in the human brain and its relevance for the development of AD. Neurology 58
(12), 1791. doi:10.1212/wnl.58.12.1791
Tixador, P., Herzog, L., Reine, F., Jaumain, E., Chapuis, J., Le Dur, A., et al. (2010).
The physical relationship between infectivity and prion protein aggregates is
strain-dependent. PLoS Pathog. 6, e1000859. doi:10.1371/journal.ppat.1000859
Tzeng, T. C., Hasegawa, Y., Iguchi, R., Cheung, A., Caffrey, D. R., Thatcher, E. J.,
et al. (2018). Inflammasome-derived cytokine IL18 suppresses amyloid-
induced seizures in Alzheimer-prone mice. Proc. Natl. Acad. Sci. U.S.A. 115,
9002–9007. doi:10.1073/pnas.1801802115
Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A.,
et al. (2012). Alzheimer amyloid-β oligomer bound to postsynaptic prion
protein activates Fyn to impair neurons. Nat. Neurosci. 15, 1227–1235.
doi:10.1038/nn.3178
Um, J. W., and Strittmatter, S. M. (2013). Amyloid-β induced signaling by cellular
prion protein and Fyn kinase in Alzheimer disease. Prion 7, 37–41. doi:10.4161/
pri.22212
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K.,
Gispert, S., et al. (2004). Hereditary early-onset Parkinson’s disease caused by
mutations in PINK1. Science 304, 1158–1160. doi:10.1126/science.1096284
van der Meer, J. W., and Simon, A. (2010). Blocking IL-1beta to slow down
progression of ALS? Proc. Natl. Acad. Sci. U.S.A. 107 (29), 12741. doi:10.1073/
pnas.1007946107
Van Everbroeck, B., Dewulf, E., Pals, P., Lubke, U., Martin, J. J., and Cras, P. (2002).
The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob
disease. Neurobiol. Aging 23, 59–64. doi:10.1016/s0197-4580(01)00236-6
Vanden Broeck, L., Callaerts, P., and Dermaut, B. (2014). TDP-43-mediated
neurodegeneration: towards a loss-of-function hypothesis? Trends Mol. Med.
20, 66–71. doi:10.1016/j.molmed.2013.11.003
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D.,
et al. (2017). Microglia-derived ASC specks cross-seed amyloid-beta in
Alzheimer’s disease. Nature 552, 355–361. doi:10.1038/nature25158
von Herrmann, K. M., Salas, L. A., Martinez, E. M., Young, A. L., Howard, J. M.,
Feldman, M. S., et al. (2018). NLRP3 expression in mesencephalic neurons and
characterization of a rare NLRP3 polymorphism associated with decreased risk of
Parkinson’s disease. NPJ Parkinsons Dis. 4, 24. doi:10.1038/s41531-018-0061-5
Wang, S., Yuan, Y. H., Chen, N. H., and Wang, H. B. (2019). The mechanisms of
NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s
disease. Int. Immunopharmacol. 67, 458. doi:10.1016/j.intimp.2018.12.019
Wang, W., Nguyen, L. T. T., Burlak, C., Chegini, F., Guo, F., Chataway, T., et al.
(2016). Caspase-1 causes truncation and aggregation of the Parkinson’s disease-
associated protein α-synuclein. Proc. Natl. Acad. Sci. U.S.A. 113, 9587–9592.
doi:10.1073/pnas.1610099113
Wang, X., Chi, J., Huang, D., Ding, L., Zhao, X., Jiang, L., et al. (2020). α-synuclein
promotes progression of Parkinson’s disease by upregulating autophagy
signaling pathway to activate NLRP3 inflammasome. Exp. Ther. Med. 19,
931–938. doi:10.3892/etm.2019.8297
Wang, X., Yan,M.H., Fujioka, H., Liu, J.,Wilson-Delfosse, A., Chen, S. G., et al. (2012).
LRRK2 regulates mitochondrial dynamics and function through direct interaction
with DLP1. Hum. Mol. Genet. 21, 1931–1944. doi:10.1093/hmg/dds003
Wendeln, A. C., Degenhardt, K., Kaurani, L., Gertig, M., Ulas, T., Jain, G., et al.
(2018). Innate immune memory in the brain shapes neurological disease
hallmarks. Nature 556, 332–338. doi:10.1038/s41586-018-0023-4
Wijeyekoon, R. S., Kronenberg-Versteeg, D., Scott, K. M., Hayat, S., Kuan, W. L.,
Evans, J. R., et al. (2020). Peripheral innate immune and bacterial signals relate
to clinical heterogeneity in Parkinson’s disease. Brain Behav. Immun. 87, 473.
doi:10.1016/j.bbi.2020.01.018
Williams, A., and Paulson, H. (2008). Polyglutamine neurodegeneration: protein
misfolding revisited. Trends Neurosci. 31 (10), 521. doi:10.1016/j.tins.2008.07.004
Williams-Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P.,
Evans, J. R., et al. (2016). Serum immune markers and disease progression in an
incident Parkinson’s disease cohort (ICICLE-PD). Mov. Disord. 31, 995–1003.
doi:10.1002/mds.26563
Williams-Gray, C. H., Wijeyekoon, R. S., Scott, K. M., Hayat, S., Barker, R. A., and
Jones, J. L. (2018). Abnormalities of age-related T cell senescence in Parkinson’s
disease. J. Neuroinflammation 15, 166. doi:10.1186/s12974-018-1206-5
Xue, Z., Zhang, Z., Liu, H., Li, W., Guo, X., Zhang, Z., et al. (2019). lincRNA-Cox2
regulates NLRP3 inflammasome and autophagy mediated neuroinflammation.
Cell Death Differ. 26 (1), 130. doi:10.1038/s41418-018-0105-8
Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., et al. (2015). Dopamine
controls systemic inflammation through inhibition of NLRP3 inflammasome.
Cell 160 (1–2), 62. doi:10.1016/j.cell.2014.11.047
Yang, L., Zhou, X., Yang, J., Yin, X., Han, L., and Zhao, D. (2008). Aspirin inhibits
cytotoxicity of prion peptide PrP106-126 to neuronal cells associated with
microglia activation in vitro. J. Neuroimmunol 199, 10–17. doi:10.1016/j.
jneuroim.2008.04.028
Yu, C. H., Davidson, S., Harapas, C. R., Hilton, J. B., Mlodzianoski, M. J.,
Laohamonthonkul, P., et al. (2020). TDP-43 triggers mitochondrial DNA
release via mPTP to activate cGAS/STING in ALS. Cell 183 (3), 636. doi:10.
1016/j.cell.2020.09.020
Zabetian, C. P., Hutter, C. M., Factor, S. A., Nutt, J. G., Higgins, D. S., Griffith, A.,
et al. (2007). Association analysis of MAPT H1 haplotype and subhaplotypes in
Parkinson’s disease. Ann. Neurol. 62, 137–144. doi:10.1002/ana.21157
Zhang, M., He, Q., Chen, G., and Li, P. A. (2020). Suppression of NLRP3
inflammasome, pyroptosis, and cell death by NIM811 in rotenone-exposed
cells as an in vitro model of Parkinson’s disease. Neurodegener. Dis. 20, 73–83.
doi:10.1159/000511207
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 64325414
Holbrook et al. Neurodegenerative Disease and the NLRP3 Inflammasome
Zhao,W., Beers, D. R., Bell, S., Wang, J., Wen, S., Baloh, R. H., et al. (2015). TDP-43
activates microglia through NF-κB and NLRP3 inflammasome. Exp. Neurol.
273, 24. doi:10.1016/j.expneurol.2015.07.019
Zhao, W., Beers, D. R., Henkel, J. S., Zhang, W., Urushitani, M., Julien, J. P., et al.
(2010). Extracellular mutant SOD1 induces microglial-mediated motoneuron
injury. Glia 58 (2), 231. doi:10.1002/glia.20919
Zhao, W., Beers, D. R., Hooten, K. G., Sieglaff, D. H., Zhang, A., Kalyana-
Sundaram, S., et al. (2017). Characterization of gene expression phenotype
in amyotrophic lateral sclerosis monocytes. JAMA Neurol. 74 (6), 677. doi:10.
1001/jamaneurol.2017.0357
Zheng, D., Liwinski, T., and Elinav, E. (2020). Inflammasome activation and
regulation: toward a better understanding of complex mechanisms. Cell Discov.
6, 36. doi:10.1038/s41421-020-0167-x
Zhou, R., Yazdi, A. S., Menu, P., and Tschopp, J. (2011). A role for mitochondria in
NLRP3 inflammasome activation. Nature 469, 221–225. doi:10.1038/
nature09663
Zhu, Q., and Kannegant, T. D. (2017). Distinct regulatory mechanisms control
proinflammatory cytokines IL-18 and IL-1β. J. Immunol. 198, 4210–4215.
doi:10.4049/jimmunol.1700352
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Holbrook, Jarosz-Griffiths, Caseley, Lara-Reyna, Poulter,
Williams-Gray, Peckham and McDermott. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 64325415
Holbrook et al. Neurodegenerative Disease and the NLRP3 Inflammasome
